> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Wins Bladder Cancer Approval After Imfinzi Regimen Cuts Death Risk 42% In Trial
- URL: https://www.bullished.co/astrazeneca-wins-bladder-cancer-approval-after-imfinzi-regimen-cuts-death-risk-42-in-trial-2d4bb564/
- Published: 2026-11-16T12:17:56.000Z
- Updated: 2026-11-16T12:17:55.000Z
- Description: The treatment expands Imfinzi's reach to patients unable or unwilling to take cisplatin, but severe adverse events were more common.
- Author: Matteo Parrino
- Tags: SEC Filings, AZN, Industry: Healthcare

[AstraZeneca](https://www.bullished.co/tag/azn/), which develops and sells prescription medicines and vaccines, received [FDA approval](https://www.sec.gov/Archives/edgar/data/901832/000165495426009811/a2426d.htm?ref=bullished.co) Monday for an Imfinzi bladder-cancer regimen that reduced the risk of death by 42% in a late-stage trial. The company's announcement covers adults with muscle-invasive disease who cannot receive or have refused cisplatin chemotherapy.

## Treatment Before And After Bladder Removal

Patients receive Imfinzi with enfortumab vedotin before surgery to remove the bladder, then Imfinzi alone afterward. The trial used three treatment cycles before surgery and nine Imfinzi cycles after it.

The FDA granted priority review to the application. Results supporting approval were presented at the 2026 European Society for Medical Oncology Congress and published simultaneously in The New England Journal of Medicine.

AstraZeneca estimates around 16,000 U.S. patients will be treated for muscle-invasive bladder cancer in 2026\. This form of the disease reaches the bladder's muscle wall; as many as 50% of patients cannot receive cisplatin because of impaired kidney function or other medical conditions.

Bladder removal alone has historically been the standard for these patients, AstraZeneca said. Approximately 50% of patients with muscle-invasive disease who undergo that surgery experience recurrence.

## Survival Gains, More Severe Adverse Events

The planned interim analysis found a [49% reduction](https://www.sec.gov/Archives/edgar/data/901832/000165495426009811/a2426d.htm?ref=bullished.co) in the combined risk of progression, recurrence, failure to undergo surgery or death. The comparison was bladder-removal surgery with or without approved postoperative treatment.

An estimated 78% of patients receiving the combination were alive at two years, versus 69% in the comparison group. The proportion alive without a qualifying disease event was 64%, compared with 45%.

Grade 3 and 4 adverse events—severe or life-threatening events—from any cause occurred in 64% of combination-treated patients, versus 44% of comparator patients. AstraZeneca said it identified no new safety signals and that patients receiving the combination maintained their reported quality of life after surgery.

The global, randomized trial enrolled 695 patients across 182 centres in 25 countries. It also tested a separate regimen containing Imjudo.

Jonathan E. Rosenberg, chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and a member of the trial's steering committee, said the regimen has the potential to become “a new standard of care in this curative-intent setting.” AstraZeneca noted that Rosenberg has financial interests related to the company.

## Imfinzi's Expanding Bladder-Cancer Reach

The approval adds another treatment setting for AstraZeneca's cancer business, whose marketed drugs include Imfinzi, Tagrisso and Enhertu. Imfinzi is an antibody treatment designed to help the immune system counter cancer's defenses.

Dave Fredrickson, AstraZeneca's executive vice president for its Oncology Haematology Business Unit, called it the company's “third bladder cancer indication in two years.”

Imfinzi is already approved in more than [50 countries](https://finance.yahoo.com/healthcare/articles/astrazeneca-gets-us-nod-expanded-080206700.html?ref=bullished.co) for muscle-invasive disease in patients eligible for cisplatin. In the U.S., Japan and other countries, it is also approved with Bacillus Calmette-Guérin induction and maintenance treatment for high-risk, non-muscle-invasive bladder cancer in patients who have not previously received that treatment.

In July 2026, AstraZeneca reported positive high-level trial results for Imfinzi plus chemotherapy in previously untreated patients with PD-L1-high urothelial cancer that could not be removed surgically, was locally advanced or had spread. The company said that combination significantly improved overall survival compared with chemotherapy.

Applications for the newly approved bladder-surgery regimen remain under review in the European Union, Japan and several other countries.

### Sources

- [Form 6-K — IMFINZI + EV APPROVED IN US IN BLADDER CANCER](https://www.sec.gov/Archives/edgar/data/901832/000165495426009811/a2426d.htm?ref=bullished.co) — SEC EDGAR
- [AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy](https://finance.yahoo.com/healthcare/articles/astrazeneca-gets-us-nod-expanded-080206700.html?ref=bullished.co) — Reuters

### More on AstraZeneca

- [AstraZeneca Wins EU Approval For Klygefa, Adding A Weekly Self-Injection Option](https://www.bullished.co/astrazeneca-wins-eu-approval-for-klygefa-adding-a-weekly-self-injection-option-15b39365/)
- [AstraZeneca Stock Soars 7%, Adding $20 Billion, As Cancer Drugs Lift Quarterly Profit](https://www.bullished.co/astrazeneca-stock-soars-7-adding-20-billion-as-cancer-drugs-lift-quarterly-profit-66c1ed74/)
- [AstraZeneca Core EPS Rises 17% To $2.79 As Cancer Drugs Absorb Farxiga Generic Hit](https://www.bullished.co/astrazeneca-core-eps-rises-17-to-2-79-as-cancer-drugs-absorb-farxiga-generic-hit-8fd6aa21/)

[All AstraZeneca (AZN) coverage →](https://www.bullished.co/tag/azn/)